AUTHORS
Niccolò Bartalucci, PhD, Danilo Tarantino, PhD2, Daniele Colazzo3, Alessio Enderti, MSC4, Sara Bianchini, MS5, Jessica Caroprese, MD6, Francesca Crupi, MD7, Gaia Ciolli, MD8, Fabiana Pancani, PhD9, Leonardo Signori, MSc10, Chiara Maccari, MS11, Matteo Piccini, MD12, Barbara Scappini, MD13, Francesco Mannelli14, Paola Guglielmelli, MD, PhD15, Alessandro Vannucchi, MD16
AFFILIATIONS
1 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
2 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
3 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
4 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
5 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
6 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
7 AOU Careggi, Florence, Italy
8 AOU Careggi, Florence, Italy
9 AOU Careggi, Florence, Italy
10 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
11 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
12 AOU Careggi, Florence, Italy
13 AOU Careggi, Florence, Italy
14 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
15 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
16 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
ABSTRACT
Background: The diagnostic and prognostic assessment of patients (pts) with acute myeloid leukemia (AML) relies on multiple cytogenetic and molecular tests whose results are required to comply with European Leukemia Net (ELN) guidelines for risk assessment. The complexity of standard, time-consuming, diagnostic assays often results in long turnaround times, possibly delaying availability of full diagnostic and prognostic profile to guide treatment choice. Aim: To overcome limitations of conventional approaches, we developed Rapid AML Mutation Detector (RAMD): a real-time analytical workflow designed to deliver exhaustive cytogenetic and molecular information as per ELN2022 criteria.
Methods: RAMD relies on a nanopore-based, long-read sequencing approach coupled to a dedicated, fully automated bioinformatic pipeline. RAMD integrates three complementary modules: a Fusion BreakPoint (FBP) module, targeting 46 known breakpoint-clusters of recurrent fusion genes; a Target Mutations module (TM), covering either CDS or hotspot regions of 15 genes for SNVs/indels, plus FLT3-ITD; a Genome Structural Variation (GSV) module, for detection of genome-wide CNVs and SVs. The procedure requires 0.2 and 1 µg of RNA (FBP-TM) and DNA (GSV), respectively, from diagnostic samples. A single flow-cell per pt is required. The RAMD workflow was first benchmarked against a banked sample series consisting of 84 AML samples fully characterized according to Gold-Standard diagnostic workflow (GS). Validation was accomplished using an independent blind cohort of 42 prospectively collected AML samples at diagnosis. Samples were collected at Hematology Unit, AOUC Florence (IRB:14560, AIRC-MYNERVA).
Results: The FBP module demonstrated 100% concordance with GS methods, correctly identifying all 23 fusion events (mean supporting reads: 427,999) present in the benchmark and validation cohorts, including the most common RUNX1::RUNX1T1, CBFB::MYH11 (types A, D, E), PML::RARA and rarer events (KMT2A-r, RUNX1::MECOM, KAT6A::CREBBP, DEK::NUP214). The TM module identified 94 mutations in the benchmark cohort, concordant with GS, but missed 4 mutations reported by GS at VAF<1.5%. Following technical optimization, TM achieved a read depth range of 9,212.7x–1,119,519x across target regions in the validation cohort and detected 100% of variants identified by GS approaches (RT-qPCR, NGS, capillary electrophoresis, and Sanger sequencing), including FLT3-ITD (n=9) and 64 SNVs/indels (22 frameshift) (Cohen's κ=1, P<0.0001). Notably, TM identified one additional CEBPA variant missed by GS, that was confirmed by orthogonal method. VAF estimates calculated using TM showed remarkable correlation with GS-NGS (ρ=0.79, P<0.0001). The GSV module showed 100% concordance with GS in the benchmark cohort for karyotype-level alterations (>2.5Mb) represented in ≥5 metaphases. In the validation cohort, mean genome-wide coverage was 26.7±5.7x. GSV analysis identified 13 cases with complex karyotype, 2 of which were cytogenetically normal or harbored only one SV by GS (karyotyping/FISH). GSV module also detected 32 additional SVs/CNVs missed by GS in 19 patients, further confirmed by target FISH or Sanger sequencing. Notably, GSV enabled SVs/CNVs characterization in 1 case with failed cell culture and 9 cases with <20 evaluable metaphases. Overall, there was a perfect concordance of patient’s assigned ELN2022 risk score between RAMD and GS. The whole RAMD process (including hands-on, sequencing and bioinformatic analysis) was completed within 62h±45’ for the GSV module, while results for the FBP and TM modules were available as early as 8h±30’ and 12h±55’, respectively, from sample receipt. In the prospective validation cohort, mimicking real-world turnaround times, complete RAMD analyses were available for all samples within ≤3.5 days of sample receipt, compared with a mean turnaround time of 15 days for the complete GS diagnostic workflow.
Conclusions: RAMD is a novel approach for exhaustive genomic characterization of pts with AML enabling accurate ELN risk classification, through a single, highly standardized sequencing and analytical workflow based on long-read sequencing. Low sample input, reduced hands-on time and costs, and flexible scalability with easy addition of novel target regions, make RAMD well suited for routine diagnostic implementation.
DISCLOSURES
Niccolò Bartalucci, PhD: No relevant conflicts of interest to declare.